Affiliations: [a] Department of Dermatology, Tel Aviv Medical Center, Tel Aviv, Israel
| [b] Department of Dermatology, Chaim Sheba Medical Center, Tel Hashomer, Israel
| [c] The Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel
| [d] Laboratorio di Patologia Clinica, Ospedale Civile, Tolmezzo, Italy
| [e] Fédération Autoimmunité et Thrombose, Laboratoire d'Immunologie Hôpital de La Conception, Marseille, France
| [f] Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Correspondence:
[*]
Corresponding author: Yaniv Sherer, The Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel. E-mail: [email protected].
Abstract: Background:Pemphigus and bullous pemphigoid are two autoimmune diseases that have similar pathogenesis. Both have a genetic predisposition, which promotes the production of auto antibodies targeted against different components of the epidermal desmosome and hemidesmosome. Antiphospholipid antibodies (aPL) are heterogeneous group of antibodies found in patients with autoimmune diseases and inflammatory conditions and are associated with thrombotic events. Objective:We sought to determine the expression profile of eight non classical aPLs in ABD patients. Methods:A cohort of 266 serum samples of patients with pemphigus, bullous pemphigoid and controls was screened for the presence of eight aPL antibodies, using the Bio-Rad BioPlex™ 2200 system. Results:Phosphatidylserine-beta-2-glycoprotein-I (aPS-β2GPI) and anti prothrombin complex (aPT-PT) serum profiles were significantly more prevalent among ABD patients; 20.7% patients with ABD compared to 5.9% of control patients were positive for aPS-β2GPI IgM. In addition, aPT-PT IgM was more prevalent among ABD patients (31% vs. 14.8%). Conclusion:aPL auto antibodies are more prevalent in ABD. Any clinical association should be further determined.
